Finances at the vaccine manufacturer Moderna began to fall almost as quickly as they had risen,as most Americans resisted getting yet another COVID booster shot. The pharmaceutical company, whose pioneering mRNA vaccine had turned it from small startup to biotech giant worth more than $100 billion in just a few years, reported a third-quarter loss last year of $3.6 billion.
In a September call aimed at shoring up investors, Moderna’s then–chief commercial officer, Arpa Garay, attributed some of the hesitancy pummeling Moderna’s numbers to uninformed vaccine skeptics. “Despite some misinformation,” Garay said, COVID-19 still drove significant hospitalizations. “It really is a vaccine that’s relevant across all age groups,” she insisted.
To get past the “misinformation” and convince the public to take continual booster shots, Garay briefly noted that Moderna was “delving down” on ways to partner “across the ecosystem to make sure consumers are educated on the need for the vaccine.”